Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
EXEL or ILMN: Which Is the Better Value Stock Right Now?
12:57pm, Tuesday, 25'th Apr 2023
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors?
Wall Street Analysts See a 36.54% Upside in Exelixis (EXEL): Can the Stock Really Move This High?
11:28am, Tuesday, 25'th Apr 2023
The consensus price target hints at a 36.5% upside potential for Exelixis (EXEL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Farallon steps up activism at biotech company Exelixis. Here's what could happen next
07:26am, Saturday, 15'th Apr 2023
Farallon isn't an activist investor, but it won't shy away from a battle if necessary.
Exelixis (EXEL) Surges 25.4% so Far in 2023: Here's Why
02:34pm, Tuesday, 11'th Apr 2023
Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.
2 Under-the-Radar Biotech Stocks to Buy in 2023
10:11am, Wednesday, 05'th Apr 2023
CRISPR Therapeutics' near-term outlook is quite bullish. There are more lucrative opportunities for Exelixis in the near future.
Farallon to launch proxy fight at biotech Exelixis: WSJ
06:23pm, Tuesday, 04'th Apr 2023
Hedge fund Farallon Capital Management plans to launch a proxy fight at cancer-drug maker Exelixis Inc. EXEL, +0.36% , and has nominated three directors to that company's board, the Wall Street Journa
Farallon Capital to Wage Proxy Battle at Biotech Firm
06:00pm, Tuesday, 04'th Apr 2023
Farallon has nominated three directors to the board of Exelixis, which develops cancer-fighting drugs.
2 Incredible Stocks to Buy With Less Than $25
10:00am, Tuesday, 04'th Apr 2023
Exelixis develops cancer drugs, a strategy that should continue to breed success. Adyen helps facilitate e-commerce across borders and is investing in its future.
Exelixis Targeted as Activist Farallon Capital Partners Reveals 7.2% Holding
10:20pm, Tuesday, 21'st Mar 2023
It has been an eventful start to the week for investors of genomics-based drug discovery outfit Exelixis (US:EXEL), after the company announced a share buyback worth $550 million pre-market and receiv
Why Exelixis Stock Leaped More Than 4% Higher Today
07:11pm, Monday, 20'th Mar 2023
The biotech announced a shareholder-pleasing bit of financial engineering. This will total as much as $550 million by the end of this year.
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
04:05pm, Monday, 13'th Mar 2023
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will provide a corporate overview at the 2023 Guggenheim Healthy Altitudes Summit on Thursday, M
2 Stocks to Buy With Less Than $20
10:07am, Friday, 10'th Mar 2023
Exelixis' exciting oncology platform can lead to new products and higher revenue. Snap's popularity among younger users remains a major long-term tailwind.
Exelixis' (EXEL) Cabozantinib Combo Study Fails to Meet Goal
02:18pm, Monday, 06'th Mar 2023
Exelixis' (EXEL) combo-drug study for kidney cancer fails to meet the primary endpoint of progression-free survival (PFS).
Exelixis Inc.: Cancer Crusader With A Bright Future
03:10am, Tuesday, 28'th Feb 2023
Exelixis has strong revenue growth and a positive outlook. Past success with a growing industry ensures demand for its products.
Exelixis (EXEL), Sairopa Obtains IND Clearance for ADU-1805
01:33pm, Tuesday, 14'th Feb 2023
Exelixiss' EXEL) partner Sairopa gets FDA clearance for its IND application for the oncology drug ADU-1805, a potential best-in-class monoclonal antibody for adults with advanced solid tumors.
